MannKind (NASDAQ:MNKD) Stock Rating Upgraded by Mizuho

Mizuho upgraded shares of MannKind (NASDAQ:MNKD) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

MNKD has been the topic of several other reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of MannKind in a report on Thursday, February 27th. Wells Fargo & Company assumed coverage on shares of MannKind in a research note on Friday, December 20th. They set an “overweight” rating and a $9.00 price target on the stock. StockNews.com raised shares of MannKind from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th. Finally, Royal Bank of Canada raised shares of MannKind from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $7.00 to $10.00 in a report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $9.56.

MannKind Trading Up 0.4 %

NASDAQ:MNKD opened at $4.66 on Wednesday. The firm’s 50 day moving average is $5.20 and its 200 day moving average is $6.07. MannKind has a 12 month low of $3.97 and a 12 month high of $7.63. The stock has a market capitalization of $1.42 billion, a PE ratio of 66.57 and a beta of 1.22.

MannKind (NASDAQ:MNKD) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. The firm had revenue of $76.78 million for the quarter, compared to analyst estimates of $74.99 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. Research analysts predict that MannKind will post 0.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MNKD. GF Fund Management CO. LTD. bought a new position in shares of MannKind in the fourth quarter worth $37,000. Jones Financial Companies Lllp boosted its stake in MannKind by 3,294.8% during the fourth quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 6,392 shares during the period. Kovitz Investment Group Partners LLC purchased a new position in MannKind during the fourth quarter worth about $65,000. Beirne Wealth Consulting Services LLC bought a new position in MannKind in the 4th quarter worth about $66,000. Finally, Marshall Investment Management LLC purchased a new stake in shares of MannKind in the 4th quarter valued at about $69,000. 49.55% of the stock is owned by institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.